Cancer News and Research

Latest Cancer News and Research

GOSH delivers world-first base-edited cell therapy for a patient with relapsed T cell leukemia

GOSH delivers world-first base-edited cell therapy for a patient with relapsed T cell leukemia

Cambridge scientists develop a comprehensive tool for predicting individual's risk of prostate cancer

Cambridge scientists develop a comprehensive tool for predicting individual's risk of prostate cancer

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

Extra year of chemotherapy lowers the risk of cancer recurrence in children with Ikaros leukemia

Extra year of chemotherapy lowers the risk of cancer recurrence in children with Ikaros leukemia

What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir?

What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir?

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma

How the COVID-19 pandemic impacted the treatment pancreatic cancer patients

How the COVID-19 pandemic impacted the treatment pancreatic cancer patients

Structural studies pave the way for cancer drugs that could target only mutated versions

Structural studies pave the way for cancer drugs that could target only mutated versions

An epigenetic modification improves the defense against infections, research shows

An epigenetic modification improves the defense against infections, research shows

Overexpression of lncRNA MVIH may serve as a potential diagnostic biomarker in cervical cancer

Overexpression of lncRNA MVIH may serve as a potential diagnostic biomarker in cervical cancer

Researchers discover a previously unknown mechanism that drives aging

Researchers discover a previously unknown mechanism that drives aging

Study may allow patients with multiple breast lesions to consider breast-conserving therapy as treatment option

Study may allow patients with multiple breast lesions to consider breast-conserving therapy as treatment option

Study proposes a new concept for treating COVID-19 associated weight loss

Study proposes a new concept for treating COVID-19 associated weight loss

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

POLAR gene profile predicts which patients may and may not benefit from radiation therapy after breast-conserving surgery

POLAR gene profile predicts which patients may and may not benefit from radiation therapy after breast-conserving surgery

Landmark study challenges a 70-year-old theory of protein folding

Landmark study challenges a 70-year-old theory of protein folding

Study finds disparities in breast cancer screening, treatment access for underserved communities

Study finds disparities in breast cancer screening, treatment access for underserved communities

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.